DanielYingWangMD

Oncology • Dallas, TX

Assistant Professor

Join to view full profile

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wang's full profile

Already have an account?

Office
5323 Harry Hines Boulevard
Dallas, TX 75390
Phone+1 972-229-0667

Fax+1 800-526-3384

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
Baylor College of MedicineResidency, Internal Medicine, 2012 - 2015
Baylor College of MedicineClass of 2012

Certifications & Licensure

TX State Medical License 2018 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

14 citations
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
Hyun-Sung Lee, Hee-Jin Jang, Maheshwari Ramineni, Daniel Y Wang, Daniela Ramos
Clinical Cancer Research. 2023-02-01
12 citations
Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access.
Marcus A Florez, Jan O Kemnade, Nan Chen, Wendy Du, Anita L Sabichi
Cancer Research Communications. 2022-07-26
6 citations
Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment.
Hee-Jin Jang, Hyun-Sung Lee, Wendong Yu, Maheshwari Ramineni, Cynthia Y Truong
Cancer Research. 2022-07-18

Journal Articles

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-cell Populations
Zeynep Eroglu, Iman Osman, Theodore S Nowicki, Antoni Ribas, Michael A Davies, Farbod Darvishian, Daniel Y Wang, Douglas B Johnson, Ravi K Amaravadi, Clinical Cancer Research

Lectures

Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Melanoma Survivor Advocates for Regular Skin Cancer ScreeningsMay 20th, 2021
Standardization Arrives for Neoadjuvant Trials in MelanomaAugust 6th, 2019